What question did this study set out to answer?

To determine whether daclizumab induction and mycophenolate mofetil permit lower tacrolimus trough levels and early steroid withdrawal without compromising graft outcomes.

May 23, 2003Clinical Transplantation

The use of an anti‐CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low‐dose tacrolimus and early withdrawal of steroids in renal transplant recipients

View Full Paper

Ask AI

Bookmark

Authors

DKDirk KuypersKU Leuven PEPieter EvenepoelKU Leuven BMBart MaesAZ Delta

Discussion

Member takes

Implication

Comparative study shows low-dose tacrolimus with daclizumab improves graft function and lowers rejection in kidney transplant recipients, indicating a safe steroid-sparing strategy.

Key Points

To determine whether daclizumab induction and mycophenolate mofetil permit lower tacrolimus trough levels and early steroid withdrawal without compromising graft outcomes.
Single-center study enrolling 82 kidney transplant recipients assigned to two immunosuppression regimens.
Group I (n = 41) received standard-dose tacrolimus (10–15 ng/mL trough), mycophenolate mofetil, and standard-dose corticosteroids.
Group II (n = 41) received daclizumab induction, low-dose tacrolimus (5–10 ng/mL trough), mycophenolate mofetil, and low-dose corticosteroids planned for cessation at 5 months.
Group II had significantly lower rates of acute rejection compared to Group I (17.1% vs 41.4%, p = 0.03), while 1-year patient survival (100% vs 95.1%) and graft survival (97.5% vs 92.6%) showed no significant differences.
One-year graft function was significantly superior in Group II versus Group I, showing lower serum creatinine (1.49 vs 1.69 mg/dL) and higher creatinine clearance (59.6 vs 49 mL/min; p < 0.05).
Delayed graft function occurred in 5% of Group II versus 12% of Group I (p = 0.43), and corticosteroids were successfully withdrawn at 5 months in 82.9% of Group II patients.

Cite This Study

Kuypers et al. (2003) studied this question.

synapsesocial.com/papers/6a904bcffdb099d0d8dd7fa0 https://doi.org/10.1034/j.1399-0012.2003.00038.x

View Full Paper

Ask AI

Bookmark

Implication

Comparative study shows low-dose tacrolimus with daclizumab improves graft function and lowers rejection in kidney transplant recipients, indicating a safe steroid-sparing strategy.

The use of an anti‐CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low‐dose tacrolimus and early withdrawal of steroids in renal transplant recipients

Discussion

Member takes

Implication

Key Points

Cite This Study

The use of an anti‐CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low‐dose tacrolimus and early withdrawal of steroids in renal transplant recipients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider